2025
Safety of Stimulants Across Patient Populations
Oliva H, Prudente T, Mayerson T, Mignosa M, Oliva I, Potenza M, Jegede O, Angarita G. Safety of Stimulants Across Patient Populations. JAMA Network Open 2025, 8: e259492. PMID: 40343695, PMCID: PMC12065045, DOI: 10.1001/jamanetworkopen.2025.9492.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRandomized clinical trialsAdverse eventsStimulant medicationData extractionSafety of stimulationRisk ratioIncreased riskMethodological quality assessmentPreferred Reporting ItemsPatient populationClinical conditionsDiverse patient populationsRisk of biasSafety of stimulant medicationsUnclear risk of biasTreatment of attention-deficit/hyperactivity disorderOverall AEsRandom-effects modelWeb of ScienceBinge eating disorderStimulant use disorderComprehensive literature searchMain OutcomesReporting Items
2024
Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
Zeng L, Perin J, Gross A, Shade D, Lanctôt K, Lerner A, Mintzer J, Brawman‐Mintzer O, Padala P, van Dyck C, Porsteinsson A, Craft S, Levey A, Herrmann N, Rosenberg P. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal Of Geriatric Psychiatry 2024, 39: e6108. PMID: 38858522, PMCID: PMC11265565, DOI: 10.1002/gps.6108.Peer-Reviewed Original ResearchConceptsMethylphenidate groupTreating apathyPlacebo-controlled trial of methylphenidateTreatment of apathyAssociated with methylphenidateEffects of methylphenidateTrial of methylphenidateAlzheimer's diseaseFollow-upNo treatment group differencesAdverse effects of methylphenidateDiastolic blood pressureSymptom ChecklistAdverse eventsTreatment group differencesMonitoring weightMethylphenidate useMethylphenidate treatmentMedical comorbiditiesPlacebo groupParticipantsMethylphenidateGroup differencesPlacebo-controlled trialMonthly visits
2023
Discriminating cocaine use from other sympathomimetics using wearable electrocardiographic (ECG) sensors
Angarita G, Pittman B, Nararajan A, Mayerson T, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. Discriminating cocaine use from other sympathomimetics using wearable electrocardiographic (ECG) sensors. Drug And Alcohol Dependence 2023, 250: 110898. PMID: 37523916, PMCID: PMC10905422, DOI: 10.1016/j.drugalcdep.2023.110898.Peer-Reviewed Original ResearchMeSH KeywordsCocaineCocaine-Related DisordersElectrocardiographyHumansMethylphenidateSympathomimeticsWearable Electronic DevicesHeterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg P, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Padala K, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. American Journal Of Geriatric Psychiatry 2023, 31: 1077-1087. PMID: 37385898, PMCID: PMC10765607, DOI: 10.1016/j.jagp.2023.06.002.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAgedAlzheimer DiseaseApathyCholinesterase InhibitorsDementiaFemaleHumansMaleMethylphenidateConceptsDiastolic blood pressureBlood pressureClinical predictorsDisease patientsAlzheimer's Disease Cooperative Study-ActivitiesHg diastolic blood pressureOptimal diastolic blood pressureMulti-center clinical trialDaily Living ScaleYears of ageAlzheimer's disease patientsHeterogeneity of responseApathy domainApathetic patientsClinical trialsFunctional impairmentTreatment benefitSignificant apathyLiving ScaleImpaired functionBaseline anxietyCholinesterase inhibitorsMedium effect sizeMethylphenidatePotential predictorsCost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
Lanctôt K, Chen C, Mah E, Kiss A, Li A, Shade D, Scherer R, Vieira D, Coulibaly H, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Burke W, Mintzer J, Herrmann N. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2). International Psychogeriatrics 2023, 35: 664-672. PMID: 37066690, PMCID: PMC10579450, DOI: 10.1017/s1041610223000327.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseApathyCentral Nervous System StimulantsHumansMethylphenidateQuality of LifeConceptsCost-consequence analysisTreatment of apathyFive-level questionnaireTrial 2Quality of lifeBinary logistic regressionPlacebo groupPlacebo treatmentMethylphenidate treatmentSignificant apathyHealth utilityResource utilization costsAlzheimer's diseaseLogistic regressionMethylphenidateTime interactionLevel questionnaireHealthcare systemCost predictorsMeasures analysisPatientsTreatmentDiseaseMonthsUtilization costs
2022
Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers
Zakiniaeiz Y, Hoye J, Ryan Petrulli J, LeVasseur B, Stanley G, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Chen MK, Matuskey D, Barron DS, Kelmendi B, Fulbright RK, Hampson M, Cosgrove KP, Morris ED. Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers. Brain Behavior And Immunity 2022, 106: 262-269. PMID: 36058419, PMCID: PMC10097458, DOI: 10.1016/j.bbi.2022.08.016.Peer-Reviewed Original ResearchConceptsEffects of LPSDopamine elevationTobacco smokersHealthy controlsSystemic inflammationDopamine systemImmune-brain interactionReward-related brain regionsAdministration of placeboAdministration of LPSSmoking statusRepeated-measures ANOVAPathophysiology of addictionDrug dosingPlaceboIndependent cohortSmokersDrug reinforcementEffect size determinationImmune systemRandomized orderBrain regionsLPSMethylphenidatePBO conditionPrescription Stimulants and the Risk of Psychosis
Gallagher KE, Funaro MC, Woods SW. Prescription Stimulants and the Risk of Psychosis. Journal Of Clinical Psychopharmacology 2022, 42: 308-314. PMID: 35489031, DOI: 10.1097/jcp.0000000000001552.Peer-Reviewed Original ResearchConceptsObservational studySystematic reviewPsychosis riskCohort studyPrescription stimulantsRetrospective cohort studyProspective cohort studyCase-control studySelf-controlled case seriesInternational Prospective RegisterLongitudinal observational studyMeta-Analyses (PRISMA) guidelinesRisk of psychosisPreferred Reporting ItemsLarge-scale observational studyMPH exposureCase seriesTherapeutic dosesProspective RegisterBias assessmentEligible studiesPsychotic eventsLower riskPsychotic symptomsReporting ItemsThe effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis
Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, Polanczyk GV, Bloch MH. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular Psychiatry 2022, 27: 1562-1572. PMID: 35027679, DOI: 10.1038/s41380-021-01391-9.Peer-Reviewed Original ResearchConceptsFixed-dose trialAttention-deficit/hyperactivity disorderDose-limiting adverse eventsChildren/adolescentsAdverse eventsFlexible-dose trialTerms of efficacyClinical practiceHigh dosesFlexible dose designIntolerable adverse eventsHyperactivity disorderIncremental benefitLikelihood of discontinuationADHD symptomsLarge systematic reviewSchool-aged children/adolescentsFlexible titrationPotential long-term effectsSymptom controlTreatment discontinuationClinical outcomesStimulant dosesDaily dosesClinical guidelines
2021
Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care?
Fredericks C. Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care? JAMA Neurology 2021, 78: 1311-1313. PMID: 34570178, DOI: 10.1001/jamaneurol.2021.2942.Peer-Reviewed Original ResearchCancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis
Chow R, Bruera E, Sanatani M, Chiu L, Prsic E, Boldt G, Lock M. Cancer-related fatigue—pharmacological interventions: systematic review and network meta-analysis. BMJ Supportive & Palliative Care 2021, 13: 274-280. PMID: 34593386, DOI: 10.1136/bmjspcare-2021-003244.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System StimulantsFatigueHumansMethylphenidateModafinilNeoplasmsNetwork Meta-AnalysisParoxetineConceptsCancer-related fatiguePharmacologic interventionsSystematic reviewCochrane Central RegisterFuture clinical trialsMore safety dataCentral RegisterHead trialsControlled TrialsCommon symptomsFuture trialsClinical trialsSafety dataDirect headMean differenceParoxetineModafinilTrialsInterventionPatientsCancer researchReviewPlaceboEMBASEMEDLINE
2020
The rate of dasotraline brain entry is slow following intravenous administration
Lew R, Constantinescu CC, Holden D, Carson RE, Carroll V, Galluppi G, Koblan KS, Hopkins SC. The rate of dasotraline brain entry is slow following intravenous administration. Psychopharmacology 2020, 237: 3435-3446. PMID: 32813030, PMCID: PMC7651685, DOI: 10.1007/s00213-020-05623-8.Peer-Reviewed Original ResearchConceptsSynaptic dopamine levelsDopamine levelsDAT occupancyPositron emission tomographyIntravenous administrationSynaptic dopamineRhesus monkeysSlow oral absorptionNorepinephrine reuptake inhibitorsBlood-brain barrierHalf-maximal displacementDopamine transporter inhibitionRecreational drug abusersBrain entryResultsIntravenous administrationReuptake inhibitorsPharmacodynamic effectsD2 receptorsRaclopride bindingAssociated elevationDasotralineDrug abusersMethylphenidateTransporter inhibitionEmission tomographyMeta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPlacebo-controlled trialPharmacological treatmentPharmacological agentsAvailable pharmacological agentsAutism spectrum disorderSerotonin reuptake inhibitorsStandardized mean differenceStandardized study designsTreatment of ASDPharmacologic treatmentPrimary outcomeReuptake inhibitorsAntipsychotic medicationSpecific assessment toolsFolinic acidSpectrum disorderModest benefitRepetitive behaviorsMean differenceStudy designSmall effect sizesIndividual studiesTrialsPlaceboNeurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate
van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. American Journal Of Geriatric Psychiatry 2020, 29: 51-62. PMID: 32461027, PMCID: PMC7641967, DOI: 10.1016/j.jagp.2020.04.026.Peer-Reviewed Original ResearchConceptsTreatment of apathyAlzheimer's diseaseCortical-basal ganglia circuitsPrefrontal cortexMotivated behaviorPublic health burdenSymptoms of apathyCatecholaminergic treatmentNeurobiologic rationaleNeuropsychiatric symptomsDopamine actionGanglia circuitsHealth burdenThalamocortical circuitsCognitive symptomsMethylphenidate actionsCatecholamine actionNeuronal circuitsSymptomsDiseaseApathetic behaviorTreatmentInitial trialMethylphenidateAD resultsEffects of sub-chronic methylphenidate on risk-taking and sociability in zebrafish (Danio rerio)
Brenner R, Oliveri A, Sinnott-Armstrong W, Levin E. Effects of sub-chronic methylphenidate on risk-taking and sociability in zebrafish (Danio rerio). Naunyn-Schmiedeberg's Archives Of Pharmacology 2020, 393: 1373-1381. PMID: 32025747, PMCID: PMC7716188, DOI: 10.1007/s00210-020-01835-z.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderSub-chronic dosesTreated with stimulant medicationVisual stimuliDecreased locomotor responseEffects of methylphenidateDeficit hyperactivity disorderRisk-takingImpaired avoidanceLocomotor responseAvoidance paradigmMethylphenidate exposureSocial stimuliStimulant medicationPsychiatric disordersHyperactivity disorderBehavioral functionsMethylphenidateNovel tankNeurobehavioral impairmentsDosing paradigmNeurobehavioral toxicityDecreased activity levelsAdult zebrafishStimuli
2019
Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release
Wai JM, Grassetti A, Slifstein M, Matuskey D, Nabulsi N, Ropchan J, Labaree D, Huang Y, Martinez D. Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release. Drug And Alcohol Dependence 2019, 205: 107627. PMID: 31669800, PMCID: PMC6893096, DOI: 10.1016/j.drugalcdep.2019.107627.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPositron emission tomographyDopamine releaseBinge drinkersHealthy controlsBinge drinkingReceptor bindingUse disordersStriatal dopamine receptor bindingYoung adult binge drinkersAdult binge drinkersAlcohol Use Disorders Identification Test (AUDIT) scoresDopamine receptor bindingFuture alcohol use disordersSubstance use disordersSignificant differencesPrevious imaging studiesOral methylphenidateRisk factorsDopamine transmissionHC subjectsAlcoholism criteriaAlcohol abuseDrinking historySignificant association
2018
Serotonin transporter inhibition and 5-HT2C receptor activation drive loss of cocaine-induced locomotor activation in DAT Val559 mice
Stewart A, Davis G, Gresch P, Katamish R, Peart R, Rabil M, Gowrishankar R, Carroll F, Hahn M, Blakely R. Serotonin transporter inhibition and 5-HT2C receptor activation drive loss of cocaine-induced locomotor activation in DAT Val559 mice. Neuropsychopharmacology 2018, 44: 994-1006. PMID: 30578419, PMCID: PMC6462012, DOI: 10.1038/s41386-018-0301-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBehavior, AnimalCocaineConditioning, ClassicalDisease Models, AnimalDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsFluoxetineLocomotionMethylphenidateMiceMice, 129 StrainMice, Inbred C57BLMice, TransgenicNeostriatumReceptor, Serotonin, 5-HT2CSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport ProteinsConceptsSerotonin (5-HT) transporterAttention-deficit/hyperactivity disorderConditioned place preferenceDA transporterLocomotor activityExtracellular DACocaine-induced locomotor activityElevation of extracellular DACocaine-induced elevationsCocaine-induced hyperlocomotionCocaine-induced locomotionElevated extracellular DAStriatal DA releaseSerotonin transporter inhibitionPlace preferenceRTI-113Cocaine actionCocaine interactionsWaiting impulsivityCocaine administrationLocomotor effectsDA releaseSerotonergic plasticityCocaine analogsAttention-deficit/hyperactivity
2017
Methylphenidate enhances implicit learning in healthy adults
Klinge C, Shuttleworth C, Muglia P, Nobre A, Harmer C, Murphy S. Methylphenidate enhances implicit learning in healthy adults. Journal Of Psychopharmacology 2017, 32: 70-80. PMID: 28946787, DOI: 10.1177/0269881117731472.Peer-Reviewed Original ResearchConceptsMeasures of cognitionImplicit cognition measuresEffects of methylphenidateCognitive measuresImplicit learningImplicit measures of cognitionDose of methylphenidateTask-switching taskCognition-enhancing effectsSensitivity to pharmacological interventionExperimental medicine studiesPharmacological interventionsPriming taskImplicit cognitionDevelopment of pharmacological interventionsImplicit measuresCognitive effectsExplicit measuresEnhance cognitionMethylphenidateHealthy volunteersCognitionAbsence of biomarkersImprove learningMale volunteersRisk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, Cohen SC, Coughlin CG, Leckman JF, Bloch MH. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. The Journal Of Clinical Psychiatry 2017, 78: e648-e655. PMID: 28682529, DOI: 10.4088/jcp.15r10601.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRisk of irritabilitySide effectsPsychostimulant medicationPsychostimulant treatmentAmphetamine derivativesPlacebo-controlled trialCommon side effectsStratified subgroup analysisEffects of amphetamineTreatment of childrenDuration of usePsychostimulant classesEligible trialsMedical comorbiditiesHead trialsSubgroup analysisRisk ratioRelative riskSTUDY SELECTIONEffective treatmentDATA SOURCESPubMed searchTrial designStimulant typeSystemic inflammation enhances stimulant-induced striatal dopamine elevation
Petrulli J, Kalish B, Nabulsi N, Huang Y, Hannestad J, Morris E. Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Translational Psychiatry 2017, 7: e1076-e1076. PMID: 28350401, PMCID: PMC5404612, DOI: 10.1038/tp.2017.18.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarbon RadioisotopesCase-Control StudiesCentral Nervous System StimulantsDopamineDopamine AntagonistsFemaleHealthy VolunteersHumansInflammationInterleukin-6Interleukin-8LipopolysaccharidesMaleMethylphenidateNeostriatumPositron-Emission TomographyRacloprideRadiopharmaceuticalsReceptors, Dopamine D2Tumor Necrosis Factor-alphaYoung AdultConceptsDA elevationSystemic inflammationImmune activationTumor necrosis factor alphaAcute immune activationImmune activator lipopolysaccharideOral methylphenidate (MPH) challengeStriatal DA levelsIL-8 concentrationsNecrosis factor alphaMesolimbic dopamine systemCross-over designPositron emission tomographyNeuroimmune systemMethylphenidate challengeDA levelsDA transmissionDopamine elevationDA dysfunctionFactor alphaBaseline scanHealthy subjectsAntagonist tracersPlaceboDopamine system
2016
Methylphenidate Modulates Functional Network Connectivity to Enhance Attention
Rosenberg MD, Zhang S, Hsu WT, Scheinost D, Finn ES, Shen X, Constable RT, Li CS, Chun MM. Methylphenidate Modulates Functional Network Connectivity to Enhance Attention. Journal Of Neuroscience 2016, 36: 9547-9557. PMID: 27629707, PMCID: PMC5039242, DOI: 10.1523/jneurosci.1746-16.2016.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderSustained attentionWhole-brain connectivity patternsFunctional brain networksHyperactivity disorderBrain networksConnectivity patternsConnectome-based predictive modeling approachWhole-brain functional connectivity patternsWhole-brain functional connectivity networksSustained attention taskStop-signal taskDose of methylphenidateFunctional network connectivityCausal roleFunctional connectivity patternsHealthy adultsAttention taskCognitive abilitiesPromising neuromarkerNetwork strengthBehavioral predictionsADHD treatmentConnectivity signaturesFunctional connectivity networks
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply